Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
OncoDNA logo — Genomic and theranostic company specializing in precision me...

OncoDNA

Genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases

Founded 2014 Belgium Belgium 52 employees Series C Total: $35.38M Biotechnology, Health Care

General Information

Company Name OncoDNA
Founded Year 2014
Location Belgium Belgium
Employees 52
Industries Biotechnology, Health Care
Funding Stage Series C
Business Model B2B, SaaS, D2C
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with OncoDNA. To contact OncoDNA, visit oncodna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OncoDNA compare?

A PDF of OncoDNA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OncoDNA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OncoDNA

OncoDNA, founded in 2012 in Belgium, is a prominent player in the Biotechnology and Health Care industries. Specializing in precision medicine, this genomic and theranostic company focuses on enhancing cancer and genetic disease treatments. Their slogan, "Genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases," encapsulates their core mission.

The company's growth trajectory is marked by strategic partnerships with leading oncology organizations and a global reach. With over 100 employees spanning multiple countries, OncoDNA integrates molecular science and clinical expertise to offer an extensive portfolio: NGS services, biomarker testing, data analysis software, and clinical decision support tools.

Their most recent financial milestone includes a $7.09M Series C investment as of 01 July 2023. OncoDNA continues to seek potential partners to further their impact in precision medicine, particularly in the oncology sector.

Business keywords: genomics, precision medicine, theranostics, cancer treatment, genetic diseases, biomarker testing, NGS services, clinical decision support, digital healthcare, molecular diagnostics, oncology, DNA sequencing, bioinformatics, medical diagnostics

Services & Products

OncoDEEP Kit
OncoSELECT Kit
OncoXPLORE Kit
Clinical Testing
Precision Enrollment
Clinical Data Intelligence (OncoCDI)
Automated Library Preparation
OncoKDM Software

Target Customers

Oncology Professionals Laboratory Professionals Pharma Companies Healthcare Institutions Biopharma Companies Researchers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $7.09M -
01 Jul 2023
Series B $20.59M 6
Verve Ventures Ackermans & van Haaren Sambrinvest
Verve Ventures, Ackermans & van Haaren +4
01 Feb 2020
Series A €7.70M 1
Ackermans & van Haaren
Ackermans & van Haaren
01 Sep 2016

Latest News

View All
Biotech consortium led by PDC*line Pharma raises €8.1M for cancer vaccine — Tech
Biotech consortium led by PDC*line Pharma raises €8.1M for cancer vaccine
Tech Jan 23, 2024

OncoDNA Alternatives & Competitors

View All Alternatives
OncoDNA vs
IntegraGen
IntegraGen France

Company specializing in the genomics of cancer and genetic diseases

Post-IPO Equity
50 employees
Biotechnology, Health Care
Compare OncoDNA vs IntegraGen
OncoDNA vs
Oxford Nanopore Technologies
Oxford Nanopore Technologies United Kingdom

Our goal is to enable the analysis of anything, by anyone, anywhere.

Post-IPO Equity
1341 employees
Biopharma, Biotechnology
Compare OncoDNA vs Oxford Nanopore Technologies
OncoDNA vs
Annoroad Genomics
Annoroad Genomics China

Annoroad, headquartered in Beijing, is the China’s leading developer and marketer on genomic innovat...

Series C
16 employees
Biotechnology, Health Care
Also compare with: OncoDNA vs ACT Genomics ACT Genomics View all alternatives

FAQ About OncoDNA

Genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases
OncoDNA was founded in 2014.
OncoDNA is headquartered in Belgium.
OncoDNA operates in Biotechnology and Health Care. Its work centres on genomics, precision medicine, theranostics and cancer treatment. Its customers include Oncology Professionals, Laboratory Professionals and Pharma Companies.
OncoDNA has a B2B, SaaS and D2C business model. Its revenue comes from Product Sales, Service Fee and Licensing.
OncoDNA has approximately 52 employees.
OncoDNA has completed 3 funding rounds, raising a total of $35.38M. The latest funding stage is Series C.
OncoDNA offers: OncoDEEP Kit, OncoSELECT Kit, OncoXPLORE Kit, Clinical Testing, Precision Enrollment, Clinical Data Intelligence (OncoCDI), Automated Library Preparation, OncoKDM Software, Project Care.
Top alternatives and competitors to OncoDNA include IntegraGen, Oxford Nanopore Technologies, Annoroad Genomics, Fabric Genomics, ACT Genomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncoDNA and IntegraGen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncoDNA, https://bouncewatch.com/company/oncodna, updated 7 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes